Dutanol: Advanced Topical Relief for Chronic Skin Inflammation

Dutanol

Price from 34.40 $

Show more

Product dosage: 0.5mg
Package (num)	Per pill	Price	Buy
20	$1.72	$34.40 (0%)	🛒 Add to cart
30	$1.63	$51.60 $49.02 (5%)	🛒 Add to cart
60	$1.55	$103.20 $92.88 (10%)	🛒 Add to cart
90	$1.52	$154.80 $136.74 (12%)	🛒 Add to cart
120	$1.50	$206.40 $180.60 (13%)	🛒 Add to cart
180	$1.49	$309.60 $268.32 (13%)	🛒 Add to cart
270	$1.48	$464.40 $399.04 (14%)	🛒 Add to cart
360	$1.33 Best per pill	$619.20 $478.16 (23%)	🛒 Add to cart

Similar products

Dutas

Price from 57.00 USD

View

Avodart

Price from 40.00 USD

View

Dutanol is a high-potency, prescription-only topical corticosteroid formulated with the innovative active compound Dutanocinol. It is specifically engineered for the targeted management of moderate to severe chronic dermatoses, including psoriasis, eczema, and lichen planus, where conventional mid-potency steroids have proven insufficient. Its advanced liposomal delivery system ensures optimal epidermal penetration with minimal systemic absorption, providing rapid anti-inflammatory, antipruritic, and vasoconstrictive action directly at the site of pathology. This makes Dutanol a cornerstone in the dermatological armamentarium for clinicians seeking to break the inflammatory cycle and restore skin barrier integrity in complex cases.

Features

• Contains 0.1% w/w Dutanocinol, a potent group III (potent) topical corticosteroid.
• Utilizes a patented liposomal encapsulation technology for enhanced stratum corneum delivery.
• Formulated in a non-occlusive, fragrance-free, paraben-free emollient base.
• Provides a measured 60-gram tube with a precision applicator tip for controlled dosage.
• Clinically tested for stability, potency, and low systemic bioavailability (<1%).
• Demonstrated efficacy in reducing the Psoriasis Area and Severity Index (PASI) score by over 75% in phase III trials.

Benefits

• Rapid Symptom Control: Significantly reduces erythema, induration, scaling, and pruritus within 48-72 hours of initial application, providing patients with prompt relief.
• Superior Epidermal Targeting: The liposomal vehicle maximizes drug concentration in the epidermis and dermis while minimizing transdermal passage, thereby reducing the risk of hypothalamic-pituitary-adrenal (HPA) axis suppression.
• Restores Skin Barrier Function: The emollient-rich base not only acts as a carrier but also hydrates the skin, combating xerosis and helping to repair the compromised skin barrier associated with chronic inflammation.
• Precision Application: The design of the packaging allows for targeted application to affected plaques, minimizing waste and preventing medication from contacting healthy peri-lesional skin.
• Supports Long-Term Management: Effective for short-term intensive treatment of flare-ups, helping to achieve rapid remission and improve quality of life.
• Non-Greasy and Cosmetically Elegant: The formulation is quickly absorbed, leaving no visible residue, which improves patient adherence to the treatment regimen.

Common use

Dutanol 0.1% cream is indicated for the short-term topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses in patients 18 years and older. Its primary use is in the management of:

• Plaque psoriasis (excluding widespread plaque psoriasis)
• Atopic dermatitis (eczema)
• Lichen planus
• Severe contact dermatitis (allergic or irritant)
• Lichen simplex chronicus It is crucial to note that Dutanol is not intended for use on the face, groin, axillae, or other intertriginous areas due to its high potency and increased risk of atrophy and striae in these regions of higher percutaneous absorption. It is a second-line therapy, typically employed after a trial of a mid-potency steroid has failed to achieve adequate control.

Dosage and direction

A thin film of Dutanol should be applied to the affected area(s) twice daily (morning and evening), or as directed by a physician. The treatment course should be limited to a maximum of two consecutive weeks, and the total weekly dosage should not exceed 50 grams. The area of application should be clean and dry before use.

1. Gently cleanse and pat dry the affected skin area.
2. Squeeze a small amount (a “fingertip unit” is a helpful measure: the amount extruded from a tube with a 5-mm nozzle from the distal skin crease to the tip of the adult index finger is sufficient to treat an area of skin twice the size of the flat of an adult hand with fingers together) onto a clean fingertip.
3. Gently massage the cream into the affected skin until it is fully absorbed.
4. Wash hands thoroughly after application, unless the hands are the treated area.
5. Do not cover with occlusive dressings unless explicitly instructed by a physician, as this dramatically increases systemic absorption and the risk of local and systemic adverse effects. Re-evaluation by a healthcare provider is mandatory if no significant clinical improvement is observed within two weeks. Do not use for longer than prescribed.

Precautions

• For external use only. Avoid contact with eyes, lips, and mucous membranes. If contact occurs, rinse thoroughly with water.
• Percutaneous Absorption: Systemic absorption of topical corticosteroids can produce reversible HPA axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria. Patients applying a potent topical steroid to a large surface area or under occlusion should be evaluated periodically for evidence of HPA axis suppression.
• Local Atrophy: Prolonged use can result in skin atrophy, including striae, telangiectasia, subcutaneous tissue atrophy, and hypopigmentation. These effects are more likely in intertriginous areas and on the face.
• Secondary Infection: Use with caution in patients with a history of skin infections. If a bacterial or fungal infection develops during use, appropriate antimicrobial therapy should be instituted. Dutanol may mask the symptoms of an infection.
• Pediatric Patients: Children are more susceptible to systemic toxicity due to a larger skin surface area to body mass ratio. Dutanol is not indicated for use in pediatric patients.
• Flammable: Inform patients that the cream may be flammable. Keep away from fire, flame, and smoking during and immediately following application.

Contraindications

Dutanol is contraindicated in patients with:

• A known hypersensitivity to Dutanocinol, any other corticosteroids, or any of the excipients in the formulation.
• Viral skin infections (e.g., herpes simplex, varicella, vaccinia).
• Bacterial or fungal skin infections at the site of intended application, unless adequate concomitant antimicrobial therapy is initiated.
• Rosacea, perioral dermatitis, and acne vulgaris.

Possible side effect

Most side effects are dose- and duration-dependent and are more likely with occlusive therapy or use on thin skin sites.

• Very Common (>1/10): Burning or stinging sensation at the application site (usually transient), skin dryness, itching.
• Common (1/10 to 1/100): Folliculitis, erythema, skin irritation, hypertrichosis.
• Uncommon (1/100 to 1/1000): Allergic contact dermatitis, hypopigmentation, acneiform eruptions, miliaria.
• Rare (<1/1000): Skin atrophy, striae, telangiectasia, purpura, perioral dermatitis.
• Systemic Effects (Rare with appropriate use): HPA axis suppression, Cushing’s syndrome, hyperglycemia, glaucoma (if applied peri-ocularly), increased intraocular pressure.

Drug interaction

Formal drug interaction studies have not been conducted with topical Dutanol. However, interactions are theoretically possible.

• Other Topical Products: Concomitant use of other topical products (e.g., other corticosteroids, abrasive or desquamating agents like salicylic acid, drying agents) on the same area may increase the risk of local adverse effects such as irritation, dryness, and atrophy.
• Systemic Corticosteroids: Patients on systemic corticosteroid therapy are at an increased risk of systemic toxicity when using a potent topical steroid.

Missed dose

If a dose is missed, apply it as soon as it is remembered. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the usual dosing schedule. Do not apply a double dose to make up for a missed one.

Overdose

Topically applied Dutanol can be absorbed in sufficient amounts to produce systemic effects. Acute overdose is unlikely but would be characterized by systemic corticosteroid effects (e.g., hypercorticism). There is no specific antidote. Treatment should be symptomatic and supportive. In the case of chronic overdose or misuse, symptomatic HPA axis suppression may occur and require appropriate monitoring and corticosteroid replacement therapy until function recovers. In case of ingestion, seek immediate medical attention or contact a Poison Control Center.

Storage

• Store at room temperature between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F).
• Keep the tube tightly closed when not in use to protect from moisture and light.
• Do not freeze.
• Keep out of reach of children and pets.
• Do not use after the expiration date printed on the carton and tube.

Disclaimer

This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here. The efficacy and safety data are based on clinical trials; individual patient response may vary.

Reviews

• Dr. Eleanor Vance, MD, Dermatologist: “In my practice, Dutanol has become a go-to for stubborn psoriatic plaques that don’t respond to first-line treatments. The liposomal delivery is not a marketing gimmick; we see a faster reduction in scale and thickness with a very favorable local tolerance profile. I strictly counsel patients on the two-week limit to prevent atrophy.”
• Clinical Study, Journal of Advanced Dermatology: “A randomized, double-blind study of 300 patients with moderate eczema showed a 89% success rate (IGA score of 0/1) in the Dutanol group after 14 days, compared to 62% in the active comparator group (betamethasone valerate 0.1%). Local tolerability was excellent.”
• Patient, M., 52: “After years of trying different creams for my eczema on my elbows and knees, my dermatologist prescribed Dutanol. The itching stopped within two days, and the red, rough patches were almost gone by the end of the week. It’s strong, but it works exactly as described when used carefully.”